Eli Lilly/$LLY
14:30
15:25
16:15
17:10
18:00
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Primary listing
NYSE
Employees
47,000
Headquarters
Website
Eli Lilly Metrics
BasicAdvanced
$963B
52.61
$20.44
0.39
$5.80
0.56%
Price and volume
Market cap
$963B
Beta
0.39
52-week high
$1,111.99
52-week low
$623.78
Average daily volume
4.1M
Dividend rate
$5.80
Financial strength
Current ratio
1.546
Quick ratio
0.724
Long term debt to equity
171.664
Total debt to equity
178.516
Dividend payout ratio (TTM)
28.28%
Interest coverage (TTM)
26.44%
Profitability
EBITDA (TTM)
28,728.6
Gross margin (TTM)
83.03%
Net profit margin (TTM)
30.99%
Operating margin (TTM)
45.16%
Effective tax rate (TTM)
18.18%
Revenue per employee (TTM)
$1,260,000
Management effectiveness
Return on assets (TTM)
17.60%
Return on equity (TTM)
96.47%
Valuation
Price to earnings (TTM)
52.611
Price to revenue (TTM)
16.258
Price to book
40.49
Price to tangible book (TTM)
84.15
Price to free cash flow (TTM)
137.271
Free cash flow yield (TTM)
0.73%
Free cash flow per share (TTM)
7.835
Dividend yield (TTM)
0.54%
Forward dividend yield
0.56%
Growth
Revenue change (TTM)
45.41%
Earnings per share change (TTM)
121.01%
3-year revenue growth (CAGR)
26.66%
10-year revenue growth (CAGR)
11.67%
3-year earnings per share growth (CAGR)
45.39%
10-year earnings per share growth (CAGR)
24.87%
3-year dividend per share growth (CAGR)
15.24%
10-year dividend per share growth (CAGR)
11.29%
What the Analysts think about Eli Lilly
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Eli Lilly Financial Performance
Revenues and expenses
Eli Lilly Earnings Performance
Company profitability
Eli Lilly News
AllArticlesVideos
S&P 500 Gains and Losses Today: Intel Soars Amid Apple Deal Rumors; Eli Lilly Stock Slides
Investopedia1 day ago
Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee
CNBC Television3 days ago
A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling
MarketBeat4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $963B as of November 29, 2025.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 52.61 as of November 29, 2025.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of November 29, 2025, the dividend rate is $5.8 and the yield is 0.56%. Eli Lilly has a payout ratio of 28.28% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment is scheduled for December 10, 2025.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.